INSYS THERAPEUTICS INC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

Phase 1

Completed

Conditions: Seizures

Interventions: Drug: Cannabidiol Oral Solution

First Posted Date: 2014-12-24

Last Posted Date: 2017-06-23

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 61

Registration Number: NCT02324673

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Miami Children's Hospital, Miami, Florida, United States

and more 7 locations

Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

Phase 3

Completed

Conditions: Seizures

Interventions: Drug: Cannabidiol Oral Solution

First Posted Date: 2014-12-17

Last Posted Date: 2018-07-26

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 52

Registration Number: NCT02318602

Locations: 🇺🇸
Granger Medical Clinic, Riverton, Utah, United States
🇺🇸
Le Bonheur Children's Hospital, Memphis, Tennessee, United States
🇺🇸
Child Neurology Center - NW F, Pensacola, Florida, United States

and more 8 locations

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome

Phase 3

Withdrawn

Conditions: Lennox-Gastaut Syndrome

Interventions: Drug: Cannabidiol Oral Solution
Drug: Placebo Solution

First Posted Date: 2014-12-17

Last Posted Date: 2018-01-04

Lead Sponsor: INSYS Therapeutics Inc

Registration Number: NCT02318537

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome

Phase 3

Withdrawn

Conditions: Dravet Syndrome

Interventions: Drug: Cannabidiol Oral Solution
Drug: Placebo Solution

First Posted Date: 2014-12-17

Last Posted Date: 2018-01-04

Lead Sponsor: INSYS Therapeutics Inc

Registration Number: NCT02318563

Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

Phase 3

Terminated

Conditions: Post-operative Pain

Interventions: Drug: Buprenorphine Sublingual Spray
Drug: Placebo

First Posted Date: 2014-12-08

Last Posted Date: 2017-08-09

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 40

Registration Number: NCT02310581

Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain

Phase 2

Withdrawn

Conditions: Acute Pain

Interventions: Drug: Morphine 6 mg
Drug: Fentanyl 100 µg
Drug: Fentanyl 200 µg
Drug: Fentanyl 400 µg
Drug: Placebo Sublingual Spray
Drug: Intravenous Placebo

First Posted Date: 2014-05-14

Last Posted Date: 2017-07-05

Lead Sponsor: INSYS Therapeutics Inc

Registration Number: NCT02137525

Locations: 🇺🇸
Wayne State University School of Medicine, Detroit, Michigan, United States
🇺🇸
Kansas University Medical Center, Kansas City, Kansas, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

and more 12 locations

Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions

Not Applicable

Completed

Conditions: Bioavailability

Interventions: Drug: Fentanyl Sublingual Spray (FSS)
Drug: Fentanyl Citrate Injection (FCI)
Drug: Naltrexone

First Posted Date: 2014-05-14

Last Posted Date: 2014-12-12

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 12

Registration Number: NCT02138396

Locations: 🇺🇸
Worldwide Clinical Trials Early Phase Services, LLC, San Antonio, Texas, United States

Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored Setting

Phase 3

Withdrawn

Conditions: Chronic Pain

Interventions: Drug: Fentanyl Sublingual Spray (FSS)
Drug: Placebo Sublingual Spray (PSS)

First Posted Date: 2014-05-14

Last Posted Date: 2018-01-04

Lead Sponsor: INSYS Therapeutics Inc

Registration Number: NCT02138409

A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users

Phase 1

Completed

Conditions: Drug Abuse, Medication

Interventions: Drug: Dronabinol 10 mg
Drug: Dronabinol 30 mg
Drug: Placebo

First Posted Date: 2014-03-24

Last Posted Date: 2014-05-13

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 43

Registration Number: NCT02094599

Locations: 🇨🇦
INC Research Toronto, Inc., Toronto, Ontario, Canada

Possible New Therapy for Advanced Cancer

Phase 1

Terminated

Conditions: Adrenocortical Carcinoma

Interventions: Drug: IL-13-PE

First Posted Date: 2013-04-16

Last Posted Date: 2015-04-27

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 9

Registration Number: NCT01832974

Locations: 🇺🇸
National Cancer Institute at the National Institutes of Health, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy